IDIA.SW Idorsia Ltd (SIX) CHF3.08 pre-market 21 Mar 2026: most active, B+ outlook

IDIA.SW stock opened pre-market at CHF 3.08 on 21 Mar 2026 with volume 1,976,535, making Idorsia Ltd one of the most active names on the SIX today. Traders are watching the biotech’s current price versus its 50-day average CHF 3.68 and its year high CHF 4.85. The combination of heavy turnover, negative EPS -0.52, and a recent technical pullback sets up a short-term trading story. Below we break down valuation, technical signals, pipeline catalysts, and Meyka AI’s grade and model forecast to frame potential entry points and risks for investors.

Market snapshot: pre-market volume and price action for IDIA.SW stock

Idorsia (IDIA.SW) is trading pre-market at CHF 3.08 after opening at CHF 3.10, with a day range CHF 2.97–3.13 and year range CHF 0.85–4.85. Volume is 1,976,535, above the 30-day average 1,711,428, marking the share among the most active on SIX. Higher relative volume with a tight intraday range suggests active repositioning by traders rather than a large directional break.

Fundamentals and valuation: how IDIA.SW stock compares in Healthcare

Idorsia shows market cap CHF 628.68M, EPS -0.52, and reported PE of -6.06 reflecting negative earnings. Price-to-sales is 2.85, and book value per share is negative CHF -4.58, signaling leverage in R&D spending. Compared with the Swiss Healthcare average PE about 26.77, IDIA.SW stock trades at a valuation consistent with an early-stage biopharma requiring catalyst delivery to re-rate.

Technical view and trading signals for IDIA.SW stock

Momentum indicators show RSI 39.49 and MACD histogram -0.07, signaling weak near-term momentum. Bollinger bands are 2.90–4.30 with the middle at 3.60, placing price close to the lower band. The stock’s 50-day average CHF 3.68 exceeds current price, while the 200-day average CHF 3.37 sits just above. Traders may watch a reclaim of CHF 3.37 as a short-covering trigger and a break below CHF 2.97 for stop-loss follow-through.

Meyka AI grade and model forecast for IDIA.SW stock

Meyka AI rates IDIA.SW with a score out of 100: 72.01 / B+ — BUY. This grade factors in S&P 500 comparison, sector and industry metrics, financial growth, key ratios, forecasts, and analyst signals. Meyka AI’s forecast model projects monthly CHF 3.53, quarterly CHF 5.23, and yearly CHF 5.60. Compared with the current price CHF 3.08, the 12‑month model implies upside of 81.70%. Forecasts are model-based projections and not guarantees.

Pipeline, catalysts and partnerships driving IDIA.SW stock momentum

Idorsia’s pipeline spans CNS, cardiovascular and immunology programs and partnerships with Janssen, Mochida, Roche, Antares, and Neurocrine. Upcoming catalysts include trial readouts and potential label expansions for daridorexant and aprocitentan programmes. Regulatory or partnership updates typically move IDIA.SW stock more than routine news because approval or licensing outcomes change revenue visibility materially.

Risks, liquidity and sector context for IDIA.SW stock

Key risks include negative operating cash flow per share CHF -0.64, long development timelines, and binary clinical outcomes. Net enterprise value to sales is high at 8.20, reflecting market expectations for future earning streams. Liquidity is adequate with average volume 1,711,428, but high volatility can widen spreads. Sector peers trade at higher PE multiples, so Idorsia must deliver clinical progress to narrow the valuation gap.

Final Thoughts

IDIA.SW stock is one of the most actively traded names in the pre-market session on 21 Mar 2026, trading at CHF 3.08 with volume 1,976,535. Short-term traders should watch technical levels: support near CHF 2.97 and resistance at the 50-day average CHF 3.68. Fundamentals show high R&D intensity, EPS -0.52, and negative book value per share CHF -4.58, which keeps the company in a binary, catalyst-driven category. Meyka AI rates IDIA.SW 72.01 (B+), BUY, and Meyka AI’s forecast model projects CHF 5.60 in 12 months, implying upside of 81.70% versus the current price. Use the model as a scenario, not a certainty: catalysts, trial readouts, and partner actions will determine if the stock reaches that level. For risk-aware investors, consider position sizing and watch the April earnings window and upcoming clinical milestones before increasing exposure. Meyka AI provides this as an AI-powered market analysis platform insight and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.